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Abstract: Hypertension in the elderly is associated with increased occurrence rates of 
sodium sensitivity, isolated systolic hypertension, and ‘white coat effect’. Arterial stiffness 
and endothelial dysfunction also increase with age. These factors should be considered in 
selecting antihypertensive therapy. The prime objective of this therapy is to prevent stroke. The 
findings of controlled trials show that there should be no cut-off age for treatment. A holistic 
program for controlling cardiovascular risks should be fully discussed with the patient, including 
evaluation to exclude underlying causes of secondary hypertension, and implementation of 
lifestyle measures. The choice of antihypertensive drug therapy is influenced by concomitant 
disease and previous medication history, but will typically include a thiazide diuretic as the 
first-line agent; to this will be added an angiotensin inhibitor and/or a calcium channel blocker. 
Beta blockers are not generally recommended, in part because they do not combat the effects 
of increased arterial stiffness. The hypertension–hypotension syndrome requires case-specific 
management. Drug-resistant hypertension is important to differentiate from faulty compliance 
with medication. Patients resistant to third-line drug therapy may benefit from treatment with 
extended-release isosorbide mononitrate. A trial of spironolactone may also be worthwhile.
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Do the mechanisms underlying hypertension  
in the elderly differ from those in younger adults?
Hypertension is a multifactorial disorder in which the mix of factors operative may 
vary according to age. Although there are no sharp dividing lines between age groups, 
age-associated trends can be recognized (Table 1). Recognition of these trends provides 
a basis for choosing age-specific approaches to clinical management.
Sodium sensitivity, defined as the extent of the rise in arterial blood pressure with 
an increase in sodium chloride intake, is heightened with age.1 In the elderly, limitation 
of dietary sodium intake and the use of diuretic agents show more effectiveness in 
controlling hypertension than in the young.2 The factors mediating the enhanced 
relationship between sodium status and change in blood pressure in the elderly are 
complex. They include an increased responsiveness of volume homeostasis to the level 
of salt intake,1 a salt-induced impairment of vascular nitric oxide (NO) production, and 
an increase in arterial stiffness.3 The systolic component of blood pressure is affected 
more than the diastolic.1,3
Isolated systolic hypertension (ISH) is characterized by systolic blood 
pressure 140 mm Hg with diastolic blood pressure 90 mm Hg, and (consequently) 
high pulse pressure.Clinical Interventions in Aging 2009:4 380
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Among older subjects, ISH occurs more frequently than 
systolic–diastolic hypertension. In the US National Health 
and Nutrition Examination Survey III (1988–1991),4 65% 
of subjects over the age of 60 were found to have ISH. 
By the sixth decade, ISH was found to be the overwhelm-
ingly predominant form of uncontrolled hypertension, 
comprising 87% of  the total. ISH arises more commonly 
from pre-existing normal blood pressure or high-normal 
blood pressure than from pre-existing diastolic hypertension.5 
In patients originally treated for systolic-diastolic hyperten-
sion, later presentation with ISH may signify the onset of 
changes in the arterial tree which are not simply a conse-
quence of the initial disorder.6
ISH is characterized by decreased arterial compliance, 
usually expressed as increase in arterial stiffness. There is 
controversy over the mechanism of the increased stiffness. 
Some attribute the effect to age-related loss of distensibility 
in the major central arteries7 as elastic tissue is progressively 
replaced with collagen.8 Other investigators attribute the 
increased arterial stiffness to endothelial dysfunction.9 
Although both factors probably contribute, the effect of 
endothelial dysfunction is potentially the more correctable 
pharmacologically.
Endothelial dysfunction is caused by free oxygen 
radicals in the arterial wall and by the upstream effects of 
reduced distal vascular flow reserve.10 Accumulation of free 
oxygen radicals results from age-associated cardiovascular 
risk factors, including atherosclerosis, diabetes mellitus, 
and renal impairment as well as hypertension itself.10 
Endothelial dysfunction manifests clinically as impair-
ment in acetylcholine-stimulated, endothelium-dependent, 
NO-mediated vasodilatation: the depressor response to 
antihypertensive agents which operate through endothelium-
dependent mechanisms is decreased, but the response to 
exogenous nitrates is preserved.11
The theory that attributes arterial stiffness to endothelial 
dysfunction is based on the following construct of how 
flow is propagated in the arterial system.12 The incident 
pressure wave generated by ventricular systole is transmitted 
freely along the viscoelastic aorta until it encounters 
arterial branching points and the peripheral resistance 
offered by muscular arterioles. Here a reflected wave 
is generated, returning retrograde towards the heart 
and augmenting the oncoming forward wave. The resulting 
pulse wave-form depends on a balance of endogenous 
vasoconstrictor and vasodilator factors in the arterial tree. 
When there is endothelial dysfunction, NO-mediated 
vasodilatation in the peripheral circulation is diminished. 
The loss of vasodilator potential results in increased 
amplitude and early return of the reflected wave, causing 
high pulse pressure.9 These characteristics are typical of the 
pulse wave found using applanation tonometry in groups 
of elderly patients with treatment-resistant ISH.11,13 The 
observation that treatment with long-acting nitrates potently 
decreased pulse wave reflection and lowered systolic blood 
pressure in these patients, despite their lack of response to 
other antihypertensive drugs, is consistent with the presence 
of endothelial dysfunction.11
The ‘white coat effect’ occurs when blood pressure 
is increased temporarily through an autonomic neural 
reaction triggered by the process of measurement. This 
effect increases with age.14 As the systolic component often 
rises more than the diastolic, the type of hypertension due 
to a ‘white coat effect’ could be mistaken for ISH. However, 
a ‘white coat effect’ can be confirmed by finding a major 
discrepancy between automated blood pressure values 
(in the normal range) and observer readings (high).14
At what blood pressure level should 
antihypertensive medication be given 
and what is the treatment goal?
In the year 2000, an advisory statement on systolic blood 
pressure in the elderly15 was issued to complement the 
Sixth Report of the Joint National Committee on the 
Prevention, Detection, Evaluation and Treatment of High 
Blood Pressure (JNC 6; 1997). The statement rejected the 
concept of age-adjusted blood pressure targets, adopting 
140/90 as the goal blood pressure (130/85 in diabetics) for 
elderly hypertensive subjects, including those with ISH. 
These guidelines were the same as those recommended by 
JNC 6 for adults in general, although in the case of ISH the 
evidence base was derived from two treatment trials (SHEP16 
and SYST-EUR)17 in which the lower limit for subject entry 
was 160/90. Since the time of publication of the advisory 
statement, further evidence from a large controlled trial 
Table 1 Age-associated trends in clinical hypertension
1.    Sodium sensitivity increases with age, as does the hypotensive 
response to diuretics
2.    Isolated systolic hypertension becomes more frequent  
than systolic–diastolic hypertension
3.     Arterial stiffness increases
4. There is a greater incidence of endothelial dysfunction
5. The frequency of ‘white coat effect’ increasesClinical Interventions in Aging 2009:4 381
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(ALLHAT)18 has supported the 140 mm Hg goal for systolic 
blood pressure in ISH.
To what age should we treat 
hypertension?
Study of the treatment of hypertension in the elderly has a 
long history. In 1895, Professor Clifford Allbutt described 
a group of five patients aged between 65 and 80 years, 
whose high arterial pressure was relieved by treatment with 
mercurial diuretics and potassium iodide, inter alia, with 
apparent symptomatic benefit.19 Ambivalence about the value 
of treating hypertension in the elderly prevailed, however, for 
many decades after that time. In clinical practice, widening 
of the pulse pressure with age was seen as compensatory 
to ‘hardening of the arteries,’ so it was feared that lowering 
the arterial pressure could cause circulatory collapse; 
in particular, it was thought that the renal circulation in 
uremic patients might be vulnerable.20 As late as 1996–1997, 
76% of a group of primary-care physicians in the USA stated 
that they would not initiate therapy for systolic blood pressure 
of 140–159 mm Hg in patients over 70 years of age.21
It was not until controlled clinical trials were reported 
in 1985 and onwards,16,22–25 that the value of antihyperten-
sive treatment in elderly patients started to become more 
universally accepted. In these trials, various combinations 
of diuretics, beta blockers, calcium channel blockers, and 
angiotensin-converting enzyme (ACE) inhibitors were given 
as the active therapy. By the year 2000, a meta-analysis of 
the trials completed in subjects aged 60 years or older, with 
systolic blood pressure 160 mm Hg and diastolic blood 
pressure 90 mm Hg, had shown that active treatment 
reduced total mortality (by 13%), and cardiovascular 
mortality (by 26%), and stroke (by 30%).26 This meta-
analysis, together with a Cochrane review summarizing 
earlier data,27 helped clearly establish the value of antihy-
pertensive agents for treating patients in their 7th and 8th 
decades. But questions remain about the benefit of such 
treatment in those even older.
Recently, the HYVET trial28 in 3,845 patients aged 
80 years or older with systolic blood pressure 160 mm Hg 
showed a 21% reduction in overall mortality and a 30% 
reduction in stroke after treatment for two years with a 
diuretic (indapamide sustained-release, 1.5 mg/day) and, if 
required, an ACE inhibitor (perindopril 2–4 mg/day). It was 
notable in this trial that fewer adverse affects were reported 
with active treatment than with placebo. The results for 
HYVET differ from those of a meta-analysis (INDANA) 
published nine years earlier.29 In 1,670 patients aged 
80 years or older, treated mainly with high-dose diuretics or 
beta-blockers, INDANA showed a 34% reduction in stroke, 
but no benefit in overall mortality. The reason for the disparity 
between these reports may reside in the choice of drugs in 
INDANA: among the very elderly, high-dose diuretics may 
pre-dispose to electrolyte disorders and sudden death; 
beta-blockers are also less effective than ACE inhibitors in 
reducing blood pressure.30
Given that the benefit of stroke prevention for future 
lifestyle holds at any age, the clinical trial findings seem 
to indicate that there is virtually no age limit at which age-
appropriate antihypertensive therapy should be withheld. 
However, a poor prognosis caused by concomitant systemic 
disease may influence a decision not to treat. Again, 
if multiple cardiovascular risk factors are present, the use 
of antihypertensive measures should be considered only in 
conjunction with the application of other cardiovascular-risk 
management strategies.
Before going on to describe drug therapy in the 
management of elderly hypertensive patients, it is neces-
sary to consider the role of diagnostic screening and the 
application of non-drug therapeutic measures.
An outline of steps in initial 
management
The presence of systolic–diastolic hypertension, or ISH, 
should be confirmed by several office measurements of 
blood pressure, preferably at more than a single visit, 
and in the supine as well as the erect posture. Ideally, 
a 24-hour recording of ambulatory blood pressure is done 
to exclude ‘white coat’ effect and to determine the circadian 
pattern of blood pressure increase. The status of pre-existing 
medical disorders will need assessment, particularly those 
that increase cardiovascular risk, such as diabetes mellitus, 
hyperlipidemia, and chronic renal failure.
As part of the routine clinical examination of the patient, 
renal and endocrine causes of hypertension should be 
excluded. Investigation for sleep apnea may also be required. 
The tests recommended are included in Table 2. Plasma 
concentrations of electrolytes, uric acid, creatinine, renin, and 
aldosterone should be measured before starting drug therapy. 
Increased plasma creatinine concentration indicates renal 
impairment: further investigation may be needed to determine 
whether this finding is caused by renal artery constriction 
or outflow tract obstruction, both potentially remediable 
conditions. Hyperuricemia denotes a risk that gout may 
be precipitated if diuretic therapy is given. Hypokalemia 
and/or a raised renin–aldosterone ratio suggest primary Clinical Interventions in Aging 2009:4 382
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aldosteronism, which can cause resistant hypertension; 
these findings would prompt a 24-hour collection of urine 
for determination of urinary aldosterone excretion rate, and 
further tests to detect a possible adrenal adenoma. Urinary 
catecholamines are measured if pheochromocytoma is to be 
excluded. Urinary microscopy and a renal ultrasound help in 
detection of underlying renal parenchymal disease or renal 
outflow obstruction. If an epigastric bruit is heard, or if there 
is disparity in renal size, computed tomography examination 
of the renal arteries may be required to exclude renal artery 
stenosis. If there is a history of daytime drowsiness or sleep 
disturbance, overnight oximetry should be done to exclude 
obstructive sleep apnea.
Is diagnostic evaluation for underlying 
causes of hypertension worthwhile  
in the elderly?
There is a tendency in clinical practice for diagnostic scrutiny 
in the elderly to be not as thorough as in younger hypertensive 
patients. It is sometimes argued that elderly subjects with 
underlying lesions causing secondary hypertension fare 
better with antihypertensive drug therapy than with surgical 
correction (achieved, for example, by renal angioplasty 
or adrenalectomy). In general, this is true for cases with 
renovascular hypertension, and possibly those with primary 
aldosteronism. However, when renal artery stenosis is 
causing renal impairment as well as hypertension, or if a 
unilateral adrenal adenoma is producing severe aldosteronism 
and treatment-resistant hypertension, surgery may be the 
better option. Additionally, knowledge of the diagnostic 
background is often important in selecting case-appropriate 
antihypertensive medication, such as spironolactone for 
primary aldosteronism caused by adrenal hyperplasia.
To what extent can elderly patients 
with hypertension be involved  
in their own clinical management?
The patient–doctor relationship is integral to a satisfactory 
outcome in managing any long-term medical disorder, and 
hypertension is no exception. The sequel to failed medical 
management of hypertension in the elderly may be a sudden 
stroke or heart attack, with severe disability or death. Yet, 
at the time of presentation most patients are suffering few 
or no symptoms. Part of the importance of the initial steps 
in detecting the presence of significant hypertension, and 
applying tests to exclude underlying causes, is the opportunity 
afforded to the doctor to establish the patient’s trust and 
to lay the ground for later implementation of therapeutic 
interventions (which the patient may find onerous).
The interaction of hypertension and other risk factors, 
as well as the adverse effects of the therapy under consid-
eration, should be explored with the patient.31 With the 
patient’s permission, an accompanying spouse, relative or 
caregiver can be included in the discussion. Cardiovascular 
risk calculators based on algorithms relating multiple risk 
factors to outcomes such as heart attack, stroke and death 
may be used to help patients weigh up the advantages and 
disadvantages of risk modification programs.32 Therapeutic 
goals should be set by common agreement between patient 
and doctor, and appointments for follow-up visits planned. 
In addition to target levels of blood pressure, goals to be set 
might include, for example, a specified weight loss, a set 
restriction of dietary salt intake, or an increase in bodily 
exercise. Options in drug therapy should be discussed 
with the patient,31 and the importance of compliance 
with medication schedules should be stressed. In a small 
minority of patients, discussion of surgical intervention, 
such as adrenalectomy or repair of renal arteries will be 
required; foreseeably, renal sympathectomy might come 
to be considered in those subjects who are refractory to 
other measures.33
Are lifestyle modifications important 
in managing elderly hypertension?
Body weight generally increases with age, and in many 
population studies, blood pressure levels have been shown 
to be directly related to body weight. Hypertension is more 
Table 2 Initial investigations recommended for newly-presenting 
elderly hypertensive patients
Plasma electrolyte concentrations
Plasma creatinine concentration
Plasma uric acid concentration
Plasma renin activity
Plasma aldosterone concentration
Plasma lipids
Urine microscopy
24-hour urinary aldosterone excretion*
24-hour urinary catecholamine excretion*
renal ultrasound
Computed tomography scan of renal arteries*
Overnight oximetry*
echocardiography
Note: *These tests are not needed in all patients.Clinical Interventions in Aging 2009:4 383
Hypertension in the elderly Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
prevalent in overweight subjects and is often hard to control.34 
In a recent study of 6,263 Spanish men and women, body 
mass and waist circumference showed a direct impact on the 
prevalence of hypertension and on the absence of control of 
blood pressure.35
The effect on blood pressure of weight loss through 
dieting varies from patient to patient. However, weight loss 
should be a goal considered in any elderly patient with a 
body mass index greater than 26. Reduced alcohol intake 
is often the key factor in a successful outcome from dietary 
measures, resulting in impressive falls in both body weight 
and blood pressure.
Blood pressure has a direct relationship to alcohol 
consumption, independent of body weight.36 In many obese 
individuals, especially among men in developed societies, 
alcohol intake represents a potent calorific source. Thus, 
alcohol restriction can have a dual effect on blood pressure: 
that operating through weight reduction due to decreased 
intake of calories, and that due to prevention of the weight-
independent pressor activity of alcohol.
Despite the evidence that sodium sensitivity is increased 
in the elderly,1 there has been a general lack of commitment 
by clinicians to the restriction of dietary sodium in elderly 
hypertensive patients. There are several reasons for this: the 
effects of sodium restriction on blood pressure in clinical trials 
have been variable; the extent of sodium deprivation required 
for an appreciable antihypertensive effect is uncertain;37 the 
need for dietary changes can be bypassed by inducing sodium 
loss with a diuretic. However, findings from controlled studies 
in older subjects with systolic hypertension have supported 
the use of low sodium diet (in the range 60–90 mmol 
per day) for decreasing blood pressure.38,39 In one study of 
24 patients with ISH, a month of usual salt intake was com-
pared to a month of reduced salt intake: a decrease in urinary 
sodium excretion from 175 ± 51 (standard deviation [SD]) 
to 87 ± 38 mmol per 24 hours was associated with a 
significant fall in systolic blood pressure from 166 ± 19 to 
156 ± 20 mm Hg.38 In another study of similar duration in 
12 patients with less severe ISH, the corresponding urinary 
excretion values were respectively 135 ± 14 and 57 ± 8 
(standard error [SE]) mmol per 24 hours; both the office 
and mean 24-hour ambulatory blood pressure values were 
significantly decreased in the low sodium phase.39
Considerable differences in sodium sensitivity are seen 
between individual hypertensive patients.1 A trial of low 
sodium diet may be worthwhile in elderly subjects with 
mild (Phase I) ISH:39 particular indications would include 
a high sodium excretion rate on usual diet, a willingness to 
modify salt intake, and a history of gout or diuretic-induced 
adverse events.
Regular aerobic exercise has been associated with modest 
blood pressure reduction in hypertensive patients overall.40 
However, reports differ as to the effect of aerobic exercise 
on hypertension in the elderly. The efficacy of moderate 
physical exercise in controlling hypertension was investigated 
in a group of elderly women, nearly half of whom had ISH. 
Systolic blood pressure was found to be significantly lower 
among those moving more than five hours per day than among 
those moving less.41 However, another trial showed that arterial 
stiffness in ISH is not modified by moderate bicycle exercise.42 
The efficacy of long-term exercise training in reversing or 
preventing arterial stiffness and hypertension needs further 
study. However, aerobic exercise increases plasma high-density 
lipoprotein cholesterol and lowers overall cardiovascular risk, 
and is of particular importance in hypertensive subjects with 
lipid disorders and diabetes mellitus. If arthritis limits walking 
or running in the elderly patient, wading or ‘aquarobics’ in a 
hydrotherapy pool are alternative ways to exercise.
Which antihypertensive drug 
regimens are suitable for treating 
elderly patients?
Selection of drug therapy for an individual patient is 
determined by considering the medical history, pre-existing 
therapy at baseline, and previous medication experiences.
The ALLHAT trial showed that a diuretic (chlorthalidone), 
given once-daily, was comparable in efficacy to a calcium 
channel blocker or ACE inhibitor for the treatment of 
hypertension, and slightly superior in preventing adverse 
cardiovascular outcomes.18 Evidence from a clinical study 
of diuretic use in ISH has been positive.43 A diuretic, 
indapamide, was shown to be more selective than an angio-
tensin II receptor blocker or calcium channel blocker for 
decreasing systolic blood pressure and pulse pressure without 
lowering normal diastolic blood pressure levels;43 as unduly 
low diastolic blood pressure is deemed to be deleterious in 
the elderly, this selectivity is a theoretical advantage.
Thus, a diuretic is a good first step in treating hypertension 
in the elderly, and a thiazide or thiazide-like diuretic is usually 
the most suitable to use. In elderly patients, some extra 
care is appropriate because of their sensitivity to diuretics. 
Inappropriately high doses may provoke hypotension, 
electrolyte disturbances or uremia. Hypokalemia is less 
likely to occur when a diuretic is combined with either a 
potassium conserving diuretic (spironolactone, amiloride) Clinical Interventions in Aging 2009:4 384
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or an angiotensin inhibitor. Diuretics may be contraindicated 
in subjects with gout, hyperuricemia, diabetes, or renal 
impairment.
Alternatively, a calcium channel blocker, an ACE inhibitor 
or angiotensin II receptor blocker can be used at the first 
step. When considering the calcium channel blocker class, 
a dihydropyridine type of calcium channel blocker may be 
better suited than a nondihydropyridine type if the hyperten-
sion is severe or if there is coincident treatment with a negative 
inotrope (eg, a beta-blocker), while a nondihydropyridine 
may be preferred if there is a personal or family history 
of ischemic stroke. An ACE inhibitor or an angiotensin II 
receptor blocker may be given in preference to a calcium 
channel blocker as a first step when there are signs of heart 
failure or left ventricular hypertrophy. Centrally-acting sym-
pathetic agonists (such as clonidine or guanfacine) have little 
role in the elderly, because of sedation and other side-effects. 
Use of peripheral alpha-adrenoceptor blockers is subject to 
a risk of postural hypotension. If beta blockers are part of 
pre-existing therapy, given, for example for arrhythmia or 
secondary prevention of myocardial infarction, then they 
should not be discontinued; however, they may show a limited 
effect on systolic blood pressure.
Many studies have shown that the effect of antihyperten-
sive therapy can be enhanced by using combinations of agents 
from different classes. Hence, if one agent fails to achieve 
control of blood pressure, one of another class should be 
added and the dosages titrated for optimal effect. If needed, 
a third agent is used. Typically, triple therapy would include a 
diuretic, an ACE inhibitor or angiotensin II receptor blocker, 
and a calcium channel blocker. Failure to achieve the systolic 
blood pressure goal with three agents indicates a need for 
thorough clinical review to exclude any underlying cause 
that may have been unrecognized during initial evaluation 
of the patient.
Why should beta blockers, 
prominent in treating hypertension 
over recent decades, be no longer 
favored for this condition?
Beta blockers had a foundational role in the combined drug 
treatment of hypertension. They were used in combination 
with a diuretic for an active treatment arm in Systolic Hyper-
tension in the Elderly Program (SHEP),16 and in other trials 
which showed a reduction of cardiovascular morbidity and 
mortality with combination therapy. However, in recent years 
their status in the treatment of  ISH has become less assured.44–46 
Findings from two major studies (LIFE47 and ASCOT-BPLA)44 
indicated that beta blockers have less efficacy than other 
antihypertensive agents in preventing stroke. It has been 
suggested that beta blockers should be no longer used in the 
primary treatment of hypertension,48 especially not in the 
elderly.49 Also, in contradistinction to other key groups of anti-
hypertensive agents, beta blockers do not decrease the arterial 
wave reflection often prominent in elderly hypertensive 
subjects,50,51 and do not rectify arterial stiffness. The Conduit 
Artery Function Evaluation study examined the chronic 
effects of atenolol ± thiazide therapy versus amlodipine ± 
perindopril therapy on central aortic blood pressures and 
hemodynamics.50 Despite similar reductions in brachial blood 
pressure with the two treatment arms, the central aortic pulse 
pressure was significantly less with amlodipine ± perindopril, 
as was augmentation index (an indicator of arterial wave 
reflection). Also, central pulse pressure and pulse wave 
reflection were found to be significantly associated with a 
composite of cardiovascular and renal morbid events. Thus, 
agents which decrease wave reflection, such as amlodipine 
and perindopril, may not only lower central pressure more 
than agents that do not, such as the beta blockers, but also may 
be associated with a better clinical outcome. However, these 
negative findings about beta blockers do not contraindicate 
their use for secondary prevention in hypertensive subjects 
with a history of heart attack.
Some management problems 
common in hypertension 
of the elderly
‘white coat effect’
As mentioned above, the condition of ‘white coat hypertension’ 
is more common in the elderly, and is often initially mistaken 
for ISH (see Table 3). In anticipation of a blood pressure 
measurement, the patient may become aware of this condition 
through a feeling of anxiety and an increased consciousness 
Table 3 Management problems in elderly hypertensive patients
Problem Steps indicated
‘white coat effect’ Automated blood pressure recording
Hypertension–hypotension 
syndrome
Measure postural changes in blood 
pressure
Inadequate response to therapy Check treatment compliance
Perform pulse wave analysis
Trial of long-acting nitrate
  Trial of spironolactoneClinical Interventions in Aging 2009:4 385
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of heart beat. Readings of blood pressure taken by an 
observer (physician or nurse) in the physician’s office are 
high, while those taken at home by the patient are normal. 
The discrepancy may become more evident when the results 
from automated 24-hour ambulatory blood pressure recording 
are compared with office readings. It has been reported that 
the white coat response elicited by observer-conducted office 
blood pressure measurements can be virtually eliminated by 
recording blood pressure with an automated device while the 
patient rests alone in a quiet room.52 ‘White coat hypertension’ 
is deemed usually not to require treatment. However, a recent 
10-year follow-up study of subjects with this syndrome 
showed that they may develop sustained hypertension, and 
may have a worse prognosis than normotensive subjects.53
Hypertension–hypotension syndrome
Elderly patients with orthostatic hypotension, a condition 
that can cause severe symptoms and morbidity, also may 
have supine hypertension. This combination has been termed 
the hypertension-hypotension syndrome.54 The hypoten-
sive component reflects dysautonomia, for which various 
disorders may be responsible. These include spinal cord 
trauma or degeneration, autonomic neuropathy, neoplastic 
disease, and drugs. Low cardiac output or plasma volume 
depletion may contribute. The hypertensive component may 
reflect increased peripheral vascular resistance, caused by 
drugs used to control orthostatic symptoms or by vascular 
stiffness arising from long-standing cardiovascular disease.
The syndrome may escape detection if blood pressure 
is not checked in the supine as well as in the erect posture. 
Coexistence of supine hypertension and orthostatic hypo-
tension poses a therapeutic dilemma, as treatment of one 
component of the syndrome can exacerbate the other.54 
Use of tilt-table studies may be helpful in the diagnosis of 
the syndrome, and in the management of the symptoms. 
Specific diagnosis of the underlying cause is often not 
possible. Treatment of the syndrome requires careful 
titration of volume expanders, sympathomimetic agents or 
beta blockers,54 so as to control postural symptoms without 
increasing supine blood pressure.
Inadequate response to therapy
Faulty compliance with therapy
If the patient’s blood pressure fails to respond to antihyperten-
sive drug therapy, faulty compliance with medication should 
be excluded. When the patient is suffering from memory loss, 
the degree of compliance with medication may be difficult 
to ascertain. Observation by the dispensing pharmacist or 
the patient’s carer may help. This is facilitated by asking the 
patient to use a multicompartment dispenser with clear plastic 
cover, through which each compartment holding tablets 
for a specified day of the week can be seen.
Having detected faulty compliance, an explanation 
should be sought. Is forgetfulness alone the cause? Does the 
patient understand the importance of taking the medication 
prescribed? Are there too many tablets, or is there difficulty 
in swallowing them? Can the patient afford the medication 
costs? Where possible, medication should be on a once-
daily basis, and the number of tablets to be taken should be 
minimized by the use of drug-combination tablets. Those 
readily available include a range of angiotensin inhibitors 
combined with a diuretic, and a calcium channel blocker 
combined with atorvastatin. Trials are in progress with 
the ‘polypill’,55 which may eventually provide further 
simplification of drug therapy for multiple indications.
resistance to drug therapy
Drug-resistant hypertension, common in ISH, can be said to 
exist when triple drug regimens fail to control the systolic 
blood pressure despite good compliance with therapy. Before 
concluding that true resistance is present, it is important 
to consider whether medications given to the patient for 
coexisting medical conditions are causing interference 
with antihypertensive treatment. In the elderly, the agents 
which most commonly cause this are non-steroidal anti-
inflammatory drugs, but sympathomimetics, some immuno-
suppressants (tacrilimus, cyclosporine), and steroid hormones 
may also be responsible. A careful drug history should be 
taken, and a trial of exclusion of any suspect compound may 
need consideration.
In true, treatment-refractory ISH, the pulse wave contor 
typically shows that the amplitude of the reflected wave is 
greatly increased. This effect is thought to be the outcome of 
stiffness of the conduit arteries. The mechanism producing 
this change is uncertain, but may relate to endothelial 
dysfunction and a consequent deficiency in NO-mediated 
vasodilator activity.
Management of drug-resistant 
hypertension
The use of exogenous NO donors to decrease  
wave reflection and pulse pressure
Theoretical basis
The unique ability of NO donors to rapidly decrease 
pulse wave reflection has been known for many years.56 
This property is due to direct effects of NO on peripheral Clinical Interventions in Aging 2009:4 386
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muscular arteries,57 and results in a fall of pulse pressure 
and systolic blood pressure with little change in diastolic 
pressure. These effects are most striking in elderly patients 
with ISH, in whom the amplitude of wave reflection 
reduction may be decreased by 40%, or more, by treatment 
with NO donors such as isosorbide mononitrate (ISMN).58 
Diuretics, calcium channel blockers and angiotensin II 
inhibitors also can decrease wave reflection, although not to 
the same extent nor as rapidly as NO donors.58 The unique 
adjuvant effect of NO donors results from their direct 
action on the cyclic guanosine monophosphate (GMP) in 
vascular smooth muscle, producing vasorelaxation through 
activation of cyclic GMP-dependent protein kinase. This 
action is endothelium-independent and is different from the 
vasodilator effects of angiotensin II inhibitors and calcium 
channel blockers, which are subject to modulation by 
endogenous NO release in the vasculature. Angiotensin II 
inhibitors are known to increase NO bioavailability,59 and to 
improve endothelium-dependent vasodilatation with long-
term use60,61 but not with short-term use.62 It may take three 
years for ACE inhibitors to restore impaired acetylcholine-
responsive vasorelaxation in hypertension.63 Thus, failure 
of response to conventional antihypertensive drugs such as 
angiotensin II inhibitors may be due, at least in the short 
term, to endothelial dysfunction. It has been speculated 
that NO donors, by maintaining peripheral vasodilatation 
through an endothelium-independent vasodilator action 
until endothelial recovery occurs, could have their greatest 
adjunctive effect in situations where endothelial dysfunction 
is currently limiting the response to other agents.11
Indications for a trial of ISMN
Conditions suggesting that an extended-release nitrate may 
be effective for the treatment of ISH are, first, failure of 
standard regimens of combination antihypertensive therapy 
to decrease systolic blood pressure below 150 mm Hg, 
and, second, a pulse pressure greater than 60 mm Hg. If a 
pulse wave analyzer, such as the SphygmoCor applanation 
tonometer (AtCor Medical, West Ryde, New South Wales, 
Australia), is available, the presence of a large reflection 
component in the pulse wave profile is a further indication 
for the use of a nitrate.
Implementing nitrate therapy
The nitrate recommended for treatment of ISH is extended-
release ISMN, in a dose of 60–120 mg/day. This should be 
given as an adjunct to the standard antihypertensive drugs 
with which the patient is being currently treated. ISMN should 
be given once-daily, thus allowing for a 12-hour interval 
when plasma nitrate level is low between doses: this may 
prevent the development of nitrate tolerance. A starting dose 
of 30–60 mg (as an ISMN extended-release formulation) is 
recommended, to be given once-daily in the morning. This 
may be increased rapidly to 120 mg once-daily if required to 
reach target systolic blood pressure. If the patient has a history 
of headaches, the starting dose should be 30 mg, in conjunc-
tion with paracetamol, 1 g, per mouth. If headache occurs, it 
often abates after the first few doses. The dosage can usually 
be increased to 120 mg daily without headache re-appearing. 
Apart from headache, which is reported in about 10% of 
patients, side-effects are rare. An important contra-indication to 
the introduction of nitrates in this, as in other clinical settings, 
is the concurrent use of sildenafil for erectile impotence.
Timing of dosage in combined use of nitrates  
with other agents
Extended-release ISMN should be given in the early morning, 
at about 8 am, as a single daily dose. This allows the effect to 
operate mainly during daylight hours when blood pressure is 
usually highest. Previous therapy should be continued without 
dosage changes, but the timing of administration may need 
adjustment. Consideration should be given to administering 
the daily dose of extended-release forms of calcium channel 
blocker or angiotensin II inhibitor drugs at night, so that their 
peak levels will occur in the early morning. This should keep 
blood pressure low at a time when circadian cardiovascular 
risk is high, and peak blood levels of ISMN are yet to be 
reached after the morning dose.
The use of aldosterone inhibitors  
in resistant hypertension
Reduction of blood pressure by aldactone has been shown 
in many clinical studies over the last 43 years (cited by 
Chapman and colleagues).64 Some of the patient populations 
studied had ‘low renin hypertension’ or raised aldosterone to 
renin ratios, indicating the possibility that cases of primary 
aldosteronism may have been included. In a patient group 
from which such cases were excluded, aldactone still 
showed antihypertensive activity when used as an add-on 
medication.65 As spironolactones (aldactone and eplerenone) 
can precipitate hyperkalemia (which may a particular hazard 
in elderly people with renal impairment), this class of diuretic 
is not recommended as first-line treatment in the elderly. 
However, aldactone may be an effective adjunct for treating 
resistant hypertension in elderly patients with intact renal 
function. The starting dose of aldactone for treating elderly Clinical Interventions in Aging 2009:4 387
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subjects with resistant hypertension should be 12.5–25 mg 
per day. The dosage can be increased to 50–75 mg per day, 
according to clinical response. The rate of onset of response is 
slow. Dosage increments should not be made more frequently 
than every two weeks. Serum potassium concentration should 
be checked during dose titration, especially in patients who 
are already receiving an ACE inhibitor or angiotensin II 
receptor antagonist.65 Gynecomastia may occur in males 
receiving long-term therapy with aldactone.
In addition to resistant cases with and without known 
primary hyperaldosteronism, those with obstructive sleep 
disorder (OSD) have come also under consideration for 
possible aldactone therapy. OSD is common amongst patients 
with resistant hypertension,66 and increasing severity of 
OSD is associated with worse control of blood pressure.67 
Possible causal links between OSD and hypertension include 
aldosterone excess.68 If patients with OSD and hypertension 
should fail to tolerate continuous positive airways pressure 
(CPAP) therapy, then it seems plausible that aldactone 
might be useful for lowering their blood pressure: however, 
this proposition has not yet been tested in clinical trials.
Conclusions
Principles in the treatment of hypertension in the elderly have 
much in common with those applying to younger age groups. 
In particular, there appears to be no cogent reason to withhold 
active therapy for hypertension in persons in their 8th or 9th 
decades of life, nor to modify the blood pressure thresholds 
above which treatment is recommended. Also, the need for 
careful investigation and treatment for underlying causes of 
secondary hypertension still applies in older persons. Issues 
especially requiring prompt separation from mainstream 
management in the elderly are ‘white coat hypertension’ 
and hypertension–hypotension syndrome. Sensitivity of 
the elderly to sodium and to diuretics enhances rather than 
reduces the value of a thiazide diuretic as the first-line 
choice in mainstream treatment. The second-line option is 
either an angiotensin inhibitor (ACE inhibitor/angiotensin II 
receptor blocker) or a calcium antagonist, depending upon 
the clinical setting. ISH, the prevalent form of hypertension 
in the elderly and characterized by arterial stiffness, is often 
resistant to combination therapy with a thiazide diuretic, 
angiotensin inhibitor, and calcium antagonist. The deficiency 
of endothelial NO-dependent vasodilatation that contributes 
to arterial stiffness may be bypassed by adjunctive treatment 
with isosorbide mononitrate. An alternative strategy for 
bringing resistant ISH under control is to add aldactone, 
a spironolactone diuretic, to existing therapy.
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